Kuwata Kazunori, Nakamura Itsuko, Ide Mika, Sato Hiroko, Nishikawa Satomi, Tanaka Masaharu
Safety Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, 1-1-1 Kazusakamatari, Kisarazu, Chiba 292-0818, Japan.
Safety Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50 Kawagishi, Toda, Saitama 335-8505, Japan.
J Toxicol Pathol. 2015 Jul;28(3):151-64. doi: 10.1293/tox.2014-0039. Epub 2015 Jun 1.
To investigate useful biomarkers associated with proximal tubular injury, we assessed changes in levels of a focused set of biomarkers in urine and blood. Male rats administered a single dose or four doses of gentamicin (GM, 240 mg/kg/day) or a single dose of cisplatin (CDDP, 5 mg/kg) were euthanized on days 2 (the day after initial dosing) 5, or 12. At each time point, histopathological examination of the kidney and immunohistochemistry for biomarkers, kidney injury molecule-1 (Kim-1), lipocalin (NGAL), clusterin (CLU), cystatin C (CysC) and β2-microglobulin (β2M) were performed. Biomarker levels were measured in urine and blood. In both treatment groups, degenerated/necrotic proximal tubules and regenerated tubules were mainly observed on days 5 and 12, respectively. At the same time as these tubular injuries, urinary Kim-1, CysC and β2M levels were increased. Moreover, urinary levels of CysC and β2M in GM-treated animals and Kim-1 in CDDP-treated animals increased (on day 2) prior to tubular injury on day 5. This was considered to reflect the characteristics of drug toxicity. Although almost all of the biomarkers in blood were not sufficiently sensitive to detect proximal tubular injury, urinary and plasma β2M levels simultaneously increased. Therefore, in addition to urinary Kim-1, CysC and β2M levels, plasma β2M levels were also considered useful for detecting proximal tubular injury.
为了研究与近端肾小管损伤相关的有用生物标志物,我们评估了尿液和血液中一组特定生物标志物水平的变化。给雄性大鼠单次或四次注射庆大霉素(GM,240mg/kg/天)或单次注射顺铂(CDDP,5mg/kg),并在第2天(初次给药后第1天)、第5天或第12天对其实施安乐死。在每个时间点,对肾脏进行组织病理学检查,并对生物标志物、肾损伤分子-1(Kim-1)、脂质运载蛋白(NGAL)、簇集素(CLU)、胱抑素C(CysC)和β2微球蛋白(β2M)进行免疫组织化学检测。测量尿液和血液中的生物标志物水平。在两个治疗组中,分别在第5天和第12天主要观察到了近端肾小管的变性/坏死和再生。与这些肾小管损伤同时,尿液中Kim-1、CysC和β2M水平升高。此外,GM处理动物尿液中的CysC和β2M水平以及CDDP处理动物尿液中的Kim-1水平在第5天肾小管损伤之前(第2天)就升高了。这被认为反映了药物毒性的特征。尽管血液中几乎所有生物标志物对检测近端肾小管损伤的敏感性都不足,但尿液和血浆中的β2M水平同时升高。因此,除了尿液中Kim-1、CysC和β2M水平外,血浆β2M水平也被认为对检测近端肾小管损伤有用。